Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Vemzatatug Vedotin · AZD0305

Antibody-drug conjugate · Cytotoxic, directed at G-protein coupled receptor family C group 5 member D (GPRC5D) · developed by ASTRAZENECA

Phase 1/2 Most advanced trial
AZN Developer

What is Vemzatatug Vedotin?

Vemzatatug vedotin (AZD0305) is an antibody-drug conjugate in which an anti-GPRC5D monoclonal antibody is linked to the microtubule-disrupting agent MMAE. After the antibody binds GPRC5D on tumor cells and the complex is internalized, MMAE inhibits tubulin polymerization, causing G2/M arrest and apoptosis. It is studied in multiple myeloma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
AZD0305
Drug type
Antibody-drug conjugate
Targets
G-protein coupled receptor family C group 5 member D (GPRC5D)
Mechanism
Cytotoxic, directed at G-protein coupled receptor family C group 5 member D (GPRC5D)
Pathways
tubulin polymerization inhibition, G2/M phase arrest, apoptosis, antibody-dependent cell-mediated cytotoxicity
Therapy area
Oncology
Developer
ASTRAZENECA (AZN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
QV6BNJ79VJ

Conditions studied

Multiple Myeloma

Other drugs acting on GPRC5D

More from ASTRAZENECA

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the AZN page.

Follow AZN, the company behind Vemzatatug Vedotin

See AZN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AZN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.